Resolution: A Phase 1 Study Evaluating The Safety And Preliminary Efficacy of ALLO-329, A Dual Anti-CD19/Anti-CD70 Allogeneic CAR T Cell Production in Autoimmune Disease

Condition: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy(ies), Systemic Sclerosis


Go To Trial Homepage